[Evaluation of ciprofloxacin versus amoxicillin + clavulanic acid or erythromycin for the empiric treatment of community-acquired pneumonia].
For the empiric management of community-acquired pneumonia, ciprofloxacin (750 mg b.i.d.) was compared with two antibiotics frequently used in this indication, i.e., amoxicillin + clavulanic acid and erythromycin. One hundred and forty-two patients were randomized in this prospective study. Among them, the 63 patients with bacteriologically documented disease were evaluated. Clinical recovery was achieved in 73.3% of patients in the ciprofloxacin group (22/30) versus 81.8% of patients in the amoxicillin + clavulanic acid or erythromycin group (27/33) (non-significant difference). Clinical failures seen with ciprofloxacin were found to be correlated with recovery of Streptococcus pneumoniae. Ciprofloxacin is effective in pneumonia but should be used only in cases where Streptococcus pneumoniae can be excluded as the causative agent.
Mouton
Y
Y
Service Universitaire des Maladies Infectieuses, CH Tourcoing, France.
Beuscart
C
C
Leroy
O
O
Ajana
F
F
Charrel
J
J
D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use*; D002939:Ciprofloxacin / Q000627:therapeutic use*; D002969:Clavulanic Acids / Q000627:therapeutic use*; D004917:Erythromycin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy*; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic
D002969:Clavulanic Acids; D002939:Ciprofloxacin; D004917:Erythromycin; D000658:Amoxicillin